王洁梅;张红平;崔璐;宁显璞;

• 1:昆明医科大学第三附属医院云南省肿瘤医院妇科

摘要(Abstract)：

外阴恶性黑色素瘤病理类型更类似于黏膜黑色素瘤,其治疗方案基于皮肤黑色素瘤,但与皮肤黑色素瘤相比,其预后更差。在手术治疗中,前哨淋巴结活检的意义不容忽视,但活检后是否立即行淋巴结清扫术尚不明确。目前外阴黑色素瘤的术后辅助治疗仍遵循皮肤黑色素瘤辅助治疗手段。随着基因测序技术的发展,外阴恶性黑色素瘤患者的治疗可能会在靶向药物治疗和免疫检查点抑制剂治疗方面获得重大突破。

关键词(KeyWords)： 黑色素瘤;黏膜黑色素瘤;外阴;治疗

Abstract:

Keywords:

基金项目(Foundation): 国家癌症中心攀登基金资助项目（No:NCC201825B77）

作者(Authors): 王洁梅;张红平;崔璐;宁显璞;

DOI: 10.13283/j.cnki.xdfckjz.2022.02.011

参考文献(References)：

• [1] Wohlmuth C,Wohlmuth-Wieser I,May T,et al.Malignant melanoma of the vulva and vagina:a us population-based study of 1863 patients[J].Am J Clin Dermatol,2020,21(2):285-295
• [2] Boer FL,Ten Eikelder MLG,Kapiteijn EH,et al.Vulvar malignant melanoma:Pathogenesis,clinical behaviour and management:review of the literature[R].Cancer Treat Rev,2019,73:91-103
• [3] Leitao MM,Jr.Management of vulvar and vaginal melanomas:current and future strategies[M].Am Soc Clin Oncol Educ Book,2014:e277-281
• [4] Verschraegen CF,Benjapibal M,Supakarapongkul W,et al.Vulvar melanoma at the M.D.Anderson Cancer Center:25 years later[J].Int J Gynecol Cancer,2001,11(5):359-364
• [5] Ragnarsson-Olding BK,Kanter-Lewensohn LR,Lagerl?f B,et al.Malignant melanoma of the vulva in a nationwide,25-year study of 219 Swedish females:clinical observations and histopathologic features[J].Cancer,1999,86(7):1273-1284
• [6] Gadducci A,Carinelli S,Guerrieri ME,et al.Melanoma of the lower genital tract:Prognostic factors and treatment modalities[J].Gynecol Oncol,2018,150(1):180-189
• [7] Phillips GL,Bundy BN,Okagaki T,et al.Malignant melanoma of the vulva treated by radical hemivulvectomy.A prospective study of the Gynecologic Oncology Group[J].Cancer,1994,73(10):2626-2632
• [8] Thomas JM.Time for comprehensive reporting of MSLT-I[J].Lancet Oncol,2006,7(1):9-11;author reply 11-12
• [9] Morton DL,Thompson JF,Cochran AJ,et al.Final trial report of sentinel-node biopsy versus nodal observation in melanoma[J].N Engl J Med,2014,370(7):599-609
• [10] Wong SL,Faries MB,Kennedy EB,et al.Sentinel lymph node biopsy and management of regional lymph nodes in melanoma:American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update[J].J Clin Oncol,2018,36(4):399-413
• [11] Morton DL.Overview and update of the phase III multicenter selective lymphadenectomy trials (MSLT-I and MSLT-II) in melanoma[J].Clin Exp Metastasis,2012,29(7):699-706
• [12] Faries MB,Thompson JF,Cochran AJ,et al.Completion dissection or observation for sentinel-node metastasis in melanoma[J].N Engl J Med,2017,376(23):2211-2222
• [13] Leiter U,Stadler R,Mauch C,et al.Final analysis of DeCOG-SLT trial:no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node[J].J Clin Oncol,2019,37(32):3000-3008
• [14] Fayne RA,Macedo FI,Rodgers SE,et al.Evolving management of positive regional lymph nodes in melanoma:Past,present and future directions[J].Oncol Rev,2019,13(2):433
• [15] Coit DG,Thompson JA,Albertini MR,et al.Cutaneous Melanoma,Version 2.2019,NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2019,17(4):367-402
• [16] Eggermont AM,Kirkwood JM.Re-evaluating the role of dacarbazine in metastatic melanoma:what have we learned in 30 years?[J]Eur J Cancer,2004,40(12):1825-1836
• [17] Patel PM,Suciu S,Mortier L,et al.Extended schedule,escalated dose temozolomide versus dacarbazine in stage IV melanoma:final results of a randomised phase III study (EORTC 18032)[J].Eur J Cancer,2011,47(10):1476-1483
• [18] Chiarion-Sileni V,Guida M,Ridolfi R,et al.Temozolomide (TMZ) as prophylaxis for melanoma brain metastases (BrM):results from a phase III,multicenter study[J].J Clin Oncol,2008,26(15_suppl):20014-20014
• [19] Danish HH,Patel KR,Switchenko JM,et al.The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma,a National Cancer Database analysis[DB].Melanoma Res,2016,26(6):595-603
• [20] Garbe C,Peris K,Hauschild A,et al.Diagnosis and treatment of melanoma.European consensus-based interdisciplinary guideline—Update 2012[J].Eur J Cancer,2012,48(15):2375-2390
• [21] 张师前，林仲秋，张颖.外阴、阴道黑色素瘤诊断与治疗的专家推荐意见(2021年版)[J].中国实用妇科与产科杂志，2021,37(7):731-739
• [22] Buchbinder EI,Gunturi A,Perritt J,et al.A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma[J].J Immunother Cancer,2016,4:52
• [23] Hodi FS,O'Day SJ,McDermott DF,et al.Improved survival with ipilimumab in patients with metastatic melanoma[J].N Engl J Med,2010,363(8):711-723
• [24] Wolchok JD,Chiarion-Sileni V,Gonzalez R,et al.Overall survival with combined nivolumab and ipilimumab in advanced melanoma[J].N Engl J Med,2017,377(14):1345-1356
• [25] Robert C,Schachter J,Long GV,et al.Pembrolizumab versus ipilimumab in advanced melanoma[J].N Engl J Med,2015,372(26):2521-2532
• [26] Robert C,Karaszewska B,Schachter J,et al.Improved overall survival in melanoma with combined dabrafenib and trametinib[J].N Engl J Med,2015,372(1):30-39
• [27] Robert C,Thomas L,Bondarenko I,et al.Ipilimumab plus dacarbazine for previously untreated metastatic melanoma[J].N Engl J Med,2011,364(26):2517-2526
• [28] Eggermont AM,Chiarion-Sileni V,Grob JJ,et al.Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy[J].N Engl J Med,2016,375(19):1845-1855
• [29] Weber J,Mandala M,Del Vecchio M,et al.Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma[J].N Engl J Med,2017,377(19):1824-1835
• [30] 赵新汉.肿瘤免疫治疗明星药——抗PD-1/PD-L1单克隆抗体[J].中国食品药品监管，2018,(10):35-41
• [31] Eggermont AMM,Blank CU,Mandala M,et al.Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma[J].N Engl J Med,2018,378(19):1789-1801
• [32] D'Angelo SP,Larkin J,Sosman JA,et al.Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma:a pooled analysis[J].J Clin Oncol,2017,35(2):226-235
• [33] Hamid O,Robert C,Ribas A,et al.Antitumour activity of pembrolizumab in advanced mucosal melanoma:a post-hoc analysis of KEYNOTE-001,002,006[J].Br J Cancer,2018,119(6):670-674
• [34] Beadling C,Jacobson-Dunlop E,Hodi FS,et al.KIT gene mutations and copy number in melanoma subtypes[J].Clin Cancer Res,2008,14(21):6821-6828
• [35] Frost MJ,Ferrao PT,Hughes TP,et al.Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant[M].Mol Cancer Ther,2002,1(12):1115-1124
• [36] Carvajal RD,Antonescu CR,Wolchok JD,et al.KIT as a therapeutic target in metastatic melanoma[J].Jama,2011,305(22):2327-2334
• [37] Hodi FS,Corless CL,Giobbie-Hurder A,et al.Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal,acral,and chronically sun-damaged skin[J].J Clin Oncol,2013,31(26):3182-3190
• [38] Kalinsky K,Lee S,Rubin KM,et al.A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal,acral,or vulvovaginal melanoma:A trial of the ECOG-ACRIN Cancer Research Group (E2607)[M].Cancer,2017,123(14):2688-2697